

Table 1. Demographic and clinical characteristics of the groups studied*

	APS	Control groups		
		Autoimmune disease	Clinical event	Healthy
Patients	139	188	38	92†
Female	111 (79.9)	164 (87.2)	21 (55.3)	58 (63.0)
Age, median years	43	42	55.5	35
Race				
Caucasian	82	110	26	56
Asian	56	77	12	36
Afro-Caribbean	1	1	0	0
Autoimmune disease				
Total	75 (54.0)	188 (100)	1 (2.6)	0 (0)
SLE	58 (41.7)	106 (56.4)	1 (2.6)	-
SS	8 (5.8)	30 (16.0)	1 (2.6)	-
Other	10 (7.2)	58 (30.9)	-	-
Thrombosis				
Total	139 (100)	0 (0)	38 (100)	0 (0)
Arterial	80 (57.6)	-	21 (55.3)	-
Venous	72 (51.8)	-	20 (52.6)	-
aPL positive				
Total	139 (100)	74 (39.4)	0 (0)	0 (0)
aCL	93 (66.9)	43 (22.9)	0 (0)	-
Anti- β_2 GPI	79 (56.8)	29 (15.4)	0 (0)	-
LAC	89 (64.0)	47 (25.0)	0 (0)	-
Antithrombotic therapy				
Total	103 (74.1)	54 (28.7)	29 (76.3)	0 (0)
Anticoagulant	58 (41.7)	52 (27.7)	6 (15.8)	-
Antiplatelet	63 (45.3)	3 (1.6)	23 (60.5)	-

* Except where indicated otherwise, values are the number (%). APS = antiphospholipid syndrome; SLE = systemic lupus erythematosus; SS = Sjögren's syndrome; aPL = antiphospholipid antibody; aCL = anticardiolipin antibody; LAC = lupus anticoagulant.

† One sample from this group was subsequently withdrawn from analysis because standard enzyme-linked immunosorbent assay revealed it to be deficient in β_2 -glycoprotein I (β_2 GPI).

Healthy control group. Samples from 93 healthy controls were collected, 92 of which were analyzed (28 from Sydney, 35 from Athens, and 29 from Sapporo). One healthy control sample was found to be deficient in β_2 GPI by standard enzyme-linked immunosorbent assay (ELISA) and was withdrawn from the study.

Demographic and clinical details of the study groups are summarized in Table 1. Institutional ethics approval for patient sampling was attained from each center participating in the study, and informed consent was obtained from all subjects prior to venipuncture. Assays were performed under blinded conditions with regard to the underlying diagnosis.

Chemicals and reagents. HEPES and streptavidin beads were purchased from Sigma. *N*-(3-maleimidylpropionyl) biocytin (MPB) was purchased from Invitrogen. All other chemicals were of reagent grade.

Proteins. Bovine serum albumin (BSA), alkaline phosphatase (AP)-conjugated anti-mouse IgG, AP-conjugated anti-rabbit IgG, and AP-conjugated anti-human IgG were from Sigma. Purified native human β_2 GPI was from Haematologic Technologies and also sourced as a kind gift from Dr. Inger Schousboe (University of Copenhagen, Denmark). Affinity-purified murine IgG2 anti- β_2 GPI monoclonal antibody (mAb) 4B2E7 (previously designated "mAb number 16") and affinity-purified rabbit anti- β_2 GPI polyclonal antibody were produced as previously described (17,18). Isotype control rabbit polyclonal IgG was purchased from BD PharMingen.

Assay for quantifying the absolute proportion of serum β_2 GPI that can be labeled with MPB. With the demonstration that β_2 GPI exists in vivo in a reduced state with free thiols (13), it was then pertinent to determine the absolute proportion of total β_2 GPI that circulates in this reduced state. This was done in experiments with a sample of pooled serum derived from 10 healthy volunteers. The sex and age distribution of the pooled serum sample was chosen to match the APS disease group.

MPB-labeled and non-MPB-labeled serum samples were acetone precipitated to remove free MPB as described previously (13). The protein pellets were then dissolved in phosphate buffered saline (PBS)-0.1% Tween to a final dilution of 4,000-fold (total volume 1,400 μ l), and streptavidin beads (50 μ l) were added. After incubation with streptavidin beads (1 hour at 4°C), the beads were removed by centrifugation for 2 minutes at 3,000g and the supernatants assayed for β_2 GPI. The proportion of β_2 GPI that was labeled with MPB was calculated as (optical density at 405 nm [OD₄₀₅] of the biotin-depleted MPB-labeled sample/OD₄₀₅ of the biotin-depleted non-MPB-labeled sample) \times 100. Validation of this method is described in full in the supplementary information (available in the online version of this article at [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1529-0131](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131)).

Assay for quantifying total human β_2 GPI. A sandwich ELISA for quantifying total β_2 GPI levels within serum/plasma samples was performed based on a previously published method (19), with modifications. Briefly, a high-binding 96-

well plate was coated overnight at 4°C with rabbit polyclonal anti-human β_2 GPI (10 nM/well). Plates were washed 4 times with PBS–0.1% Tween and then blocked with 2% BSA/PBS–0.1% Tween for 1 hour at room temperature. Following washing, 100 μ l of anti-human β_2 GPI mouse mAb (clone 4B2E7) was added (10 nM/well, diluted in 0.25% BSA/PBS–0.1% Tween) and then 100 μ l of the patient sample diluted 4,000-fold in PBS–0.1% Tween was coincubated for 1 hour at room temperature. After washing 4 times with PBS–0.1% Tween, AP-conjugated goat anti-mouse IgG was added (1:1,500 dilution) and incubated for 1 hour at room temperature, and samples read at OD₄₀₅ after addition of chromogenic substrate. An in-house standard, consisting of pooled serum from 10 healthy controls, was used to construct a standard curve for every ELISA. The level of β_2 GPI in the pooled-serum in-house standard was determined initially using a β_2 GPI in-house standard curve and then validated with a calibrator from a commercially available β_2 GPI quantification kit (Hyphen BioMed). Each new batch of the pooled-serum in-house standard was recalibrated against the commercial calibrator. Samples were assayed in duplicate.

Within-plate coefficients of variation (CVs) for this ELISA were calculated by running 10 duplicates of the same patient sample on a single plate. Between-plate CVs were calculated by taking 10 independent assays performed consecutively on separate days and calculating the CV based on the variation of the number obtained by dividing the OD of the standard at 4,000-fold dilution by the OD of the standard at 8,000-fold dilution for each plate.

Assay for measuring the relative amount of β_2 GPI with free thiols within patient samples as compared to a pooled-serum in-house standard sample. The amount of β_2 GPI with free thiols in patient samples relative to the standard sample was assayed as previously described (13), with minor modifications. Measurement of the amount of β_2 GPI that is reduced is based on labeling of free thiols of β_2 GPI with the biotin-conjugated selective free thiol binding reagent MPB, capturing biotin-labeled proteins on a streptavidin plate, and detecting the presence of MPB-labeled β_2 GPI with a specific anti- β_2 GPI mAb. The mean \pm SD within-plate CV for this ELISA is 5.08 \pm 3.09%, and the between-plate CV is 6.25% (13).

MPB (4 mM) was added to 50 μ l of patient plasma or serum and incubated for 30 minutes at room temperature in the dark with agitation, diluted 50-fold in 20 mM HEPES buffer (pH 7.4), and incubated for a further 10 minutes at room temperature in the dark. Unbound MPB was then removed by acetone precipitation. The protein pellet was resuspended in PBS–0.05% Tween (final dilution 100-fold). The samples were then diluted a further 40-fold (4,000 times final), added in duplicate to a streptavidin-coated 96-well plate (100 μ l/well; Nunc), and incubated for 90 minutes at room temperature. Prior to addition of MPB-labeled serum samples, streptavidin-coated plates were washed 3 times with PBS–0.1% Tween and blocked with 2% BSA/PBS–0.1% Tween. After washing 3 times with PBS–0.1% Tween, the murine anti- β_2 GPI mAb (clone 4B2E7) was added (25 nM) and incubated for 1 hour at room temperature. After 3 further washings with PBS–0.1% Tween, AP-conjugated goat anti-mouse IgG (1:1,500 dilution) was added for 1 hour at room temperature and samples read at 405 nm after addition of chromogenic

substrate. For each experiment, the pooled in-house standard used for the above-described β_2 GPI quantification ELISA was MPB labeled, acetone precipitated, and used as an internal control and standard. The degree of MPB labeling in each patient sample was expressed as a percentage of that observed with the pooled in-house standard, after correction for the total amount of β_2 GPI. The proportion of non-MPB-labeled β_2 GPI represents the oxidized form of the molecule.

Statistical analysis. Box plots were created to depict the distributions of β_2 GPI across groups. Medians and interquartile ranges (IQRs) were calculated. For comparisons between individual samples, the Mann-Whitney U test was used. Odds-ratios (ORs) and 95% confidence intervals (95% CIs) of exposure or disease incidence were computed using logistic regression. Adjustment for age and sex was carried out to remove potential confounders linked to these predictors.

RESULTS

A significant proportion of β_2 GPI in vivo in healthy volunteers circulates in the reduced form. We have recently demonstrated that β_2 GPI circulates in vivo in a reduced form (13), and we therefore wished to determine the absolute proportion of β_2 GPI that is in this biochemically reduced state. This was investigated using a sample of human serum pooled from 10 healthy volunteers. Figure 1 shows that a mean of 45.6% of β_2 GPI in pooled serum from healthy subjects was labeled with the biotin-conjugated free thiol binding reagent MPB. Validation of this method is demonstrated in detail in Supplementary Figure 1, available in the online version of this article at [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1529-0131](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131).

Total β_2 GPI levels are elevated in APS and are associated with thrombogenic pathogenicity in aPL-positive patients. Given that biochemically reduced β_2 GPI was found to represent a large proportion of circulating β_2 GPI in healthy subjects, it was then relevant to ascertain whether this level was altered in patients with APS as compared to both disease control and healthy control groups. Serum or plasma levels of total β_2 GPI were quantified in each individual patient sample so that a relative proportion of reduced and oxidized β_2 GPI could be calculated for each sample.

The assay used for detecting total levels of β_2 GPI in patient serum and plasma was optimized for use with in-house anti- β_2 GPI antibodies, as shown in Supplementary Figure 2 ([http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1529-0131](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131)). The within-plate CV for this assay was 5.8% and the between-plate CV was 3.3%, indicating good reproducibility.

The median level of total β_2 GPI in the healthy control group was 178.4 μ g/ml (IQR 149.4–227.5) (n = 91). In addition to healthy controls, an autoimmune




Figure 1. Beta-2-glycoprotein I (β_2 GPI) with free thiols represents a large proportion of total circulating β_2 GPI in vivo. Pooled serum from 10 healthy volunteers was labeled with *N*-(3-maleimidylpropionyl) biocytin (MPB) (4 mM) or treated with control buffer alone, after which the MPB-labeled proteins were depleted by incubation with streptavidin beads. Both samples were then centrifuged at 3,000g for 10 minutes to remove the beads, and an enzyme-linked immunosorbent assay for total β_2 GPI was performed on the supernatant of both MPB-labeled and non-MPB-labeled samples post-streptavidin incubation. The relative reduction (in optical density) of the MPB-labeled sample as compared to the non-MPB-labeled sample indicates the relative amount of β_2 GPI with free thiols labeled with MPB. Values are the mean \pm SD.

disease control group (autoimmune disease with or without aPL but without APS) and a clinical event control group (thrombosis without aPL) were included, as described above. As shown in Figure 2A, the concentration of total β_2 GPI was significantly higher in the APS group (median 216.2 μ g/ml [IQR 173.3–263.8]) ($n = 139$) as compared to the healthy control group ($P < 0.0002$), the autoimmune disease control group ($P < 0.0001$), and the clinical event control group ($P < 0.0001$). Compared to healthy controls, cases were twice as likely to have an elevated β_2 GPI level (defined as plasma levels ≥ 200 μ g/ml). The effect remained after adjustment for age and sex (OR 2.2 [95% CI 1.2–3.9]). Given that the odds ratios of disease and of exposure can be considered the same, this translates to a 2-fold increase in thrombosis for patients with elevated β_2 GPI




Figure 2. Elevated levels of β_2 -glycoprotein I (β_2 GPI) in patients with the antiphospholipid syndrome (APS). **A.** Total β_2 GPI in the serum of patients with thrombosis-associated APS and in the serum of patients in the 3 control groups, i.e., healthy controls, patients with autoimmune disease (AID) with or without antiphospholipid antibodies (aPL) but without APS, and patients with clinical thrombotic events without APS. **B.** Total β_2 GPI in the serum of patients in the APS group who had an autoimmune disease compared to patients in the autoimmune disease control group who were positive for aPL and patients in the autoimmune disease control group who were negative for aPL. Elevated levels of β_2 GPI were demonstrated only when aPL positivity was combined with a thrombotic clinical event. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers.

levels, in the absence of further confounding effects. The association was stronger when the comparison was with the control group consisting of patients with autoimmune disease with or without aPL (OR 4.6 [95% CI 2.9–7.5]). It is also possible to treat total β_2 GPI as a continuous variable in the model. When this was done, the results were consistent with the other findings (i.e., there was a strong positive association between total β_2 GPI level and thrombosis risk).

Figure 2B shows that elevated β_2 GPI levels were observed only when persistent aPL positivity was combined with a thrombotic event, thus fulfilling classification criteria for APS. Levels of β_2 GPI in the autoimmune disease controls (without thrombotic events) with persistent aPL did not differ from levels in autoimmune disease controls without aPL, and also were not different from levels in healthy controls.

Subgroup analysis of the total level of β_2 GPI within the APS group revealed no differences between those with and those without an additional autoimmune disease. Furthermore, there was no difference between those with arterial thrombosis and those with venous thrombosis (Supplementary Figure 3, [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1529-0131](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131)).

APS is associated with a greater proportion of β_2 GPI being in an oxidized state. Each patient sample was labeled with MPB, and the amount of β_2 GPI in the reduced form was compared and expressed as a percentage of that observed in a pooled standard (derived from 10 healthy volunteers who were matched for age and sex with the APS group), after correction for the total amount of β_2 GPI. The same in-house pooled standard was used for every MPB labeling experiment and assay. The sensitivity for detecting reduced β_2 GPI with this assay extends to a dilution of >128,000-fold, indicating marked sensitivity (Figure 3). The linear range was found to be between dilutions of 400- and 128,000-fold. The dilution found to yield ~50% of maximum OD was found to be 1:4,000, and hence this dilution was used to screen all patient samples for reduced β_2 GPI. This assay has previously been shown to yield identical results when serum and plasma sampled from the same patient are tested in parallel (13).

Figure 4 shows that the relative proportion of β_2 GPI in the reduced form, expressed as a percentage of that observed with the in-house standard, was significantly less in APS patients presenting with vascular thrombosis as compared to healthy controls, autoimmune disease controls, and clinical event controls (all




Figure 3. High level of sensitivity of the assay for quantifying relative amounts of reduced β_2 GPI. Pooled human serum from healthy volunteers ($n = 10$) was labeled with MPB, and a streptavidin-coated plate-based enzyme-linked immunosorbent assay for reduced β_2 GPI was performed on varying dilutions of this labeled sample, as described in Patients and Methods. The linear range for this assay was at dilutions between 1:400 and 1:128,000. OD = optical density (see Figure 1 for other definitions).

$P < 0.0001$). Thus, β_2 GPI in APS patients presenting with thrombosis is in an oxidized state relative to each of the other 3 control groups. Similar to the findings in the analysis of total β_2 GPI, a lower level of the reduced β_2 GPI (proportion $\leq 50\%$) was associated with a greater risk of thrombosis. An OR of 4.1 (95% CI 1.9–8.8) in relation to healthy subjects was observed after adjustment for age and sex. A similar but somewhat smaller effect (OR 2.0 [95% CI 1.2–3.4]) was also obtained when the reference group was patients with autoimmune disease with or without aPL but without thrombosis.

Patient positivity for lupus anticoagulant (LAC) activity has been reported to be a strong predictor of thrombosis compared to anti- β_2 GPI or anticardiolipin antibodies without LAC activity, particularly with regard to arterial thrombosis and the development of stroke (4,20). Subgroup analysis of the various aPL subtypes within the APS group revealed that the proportion of β_2 GPI circulating in the reduced state was significantly lower in the APS patients who were positive for both anti- β_2 GPI and LAC as compared to those positive for anti- β_2 GPI but not LAC (median 53.58% [IQR 39.18–73.56] [$n = 45$] versus 74.80% [IQR 60.69–84.51] [$n =$




Figure 4. Circulation of β_2 GPI in an oxidized form in patients with APS. Levels of β_2 GPI in the reduced form were assayed and expressed as a percentage of that observed in an in-house standard (pooled serum from 10 healthy volunteers) after correction for the total amount of β_2 GPI. The same pooled standard was used throughout. APS patients presenting with thrombosis had significantly lower amounts of β_2 GPI in the reduced form as compared to each of the 3 control groups. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers. See Figure 2 for definitions.

29]; $P \leq 0.001$) (Figure 5). Interestingly, levels of β_2 GPI were also lower in APS patients presenting with arterial thrombosis only (median 53.81% [IQR 39.38–74.62] [$n = 67$]) versus those presenting with venous thrombosis only (62.09% [IQR 49.64–83.11] [$n = 59$]) ($P < 0.045$), as shown in Supplementary Figure 4, [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1529-0131](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131).

DISCUSSION

This is, to our knowledge, the first reported demonstration that the redox state of the autoantigen β_2 GPI, in conjunction with plasma concentration levels, is different in APS patients compared to healthy or disease control subjects. Our study is the first to definitively confirm that β_2 GPI levels are elevated in APS patients—both those with and those without an additional autoimmune disease—as compared to healthy and disease control groups. The finding of elevated levels of

β_2 GPI was observed by our group previously, albeit utilizing far lower numbers of patients (19). In addition, it is reported herein that levels of oxidized β_2 GPI are elevated in APS patients compared to healthy and disease controls. A novel assay to measure relative amounts of reduced β_2 GPI, as well as the ELISA for total β_2 GPI, had good reproducibility and demonstrated strong associations with the APS disease phenotype. The robust nature of these findings is highlighted by the large numbers of well-characterized patients (>450) screened through this large international collaborative multi-center effort coupled with the use of both healthy and 2 distinct disease control groups. Such assays that precisely quantify the amount of posttranslationally modified autoantigen are unique in the field of APS, and even autoimmunity.

An extensive number of in vitro and in vivo studies suggest that anti- β_2 GPI autoantibodies in complex with β_2 GPI directly contribute to the APS clinical phenotype of thrombosis (5). In the present study, we




Figure 5. Association of positivity for anti- β_2 GPI combined with lupus anticoagulant (LAC) with an elevated proportion of β_2 GPI circulating in an oxidized state. Samples from APS patients presenting with vascular thrombosis who were positive for both anti- β_2 GPI and LAC had significantly lower amounts of β_2 GPI in the reduced form as compared to those from patients who were positive for anti- β_2 GPI but not for LAC. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers. See Figure 2 for other definitions.

have demonstrated that patients who are persistently positive for aPL and have the clinical features of APS have higher levels of total and oxidized β_2 GPI compared to controls. It is reasonable to hypothesize that clinical states associated with an increased oxidative stress load, such as pregnancy and infection (21), may lead to further increases in the levels of oxidized β_2 GPI in the plasma, potentially elevating the risk of pathologic thrombosis in patients who are positive for anti- β_2 GPI antibodies. This is based on the premise that an increased plasma load of oxidized β_2 GPI may lower the threshold for provoking an anti- β_2 GPI autoantibody-mediated dysregulated prothrombotic response. A recent study demonstrated that oxidative stress may drive β_2 GPI production in vivo through activator protein 1 and NF- κ B-mediated up-regulation of β_2 GPI gene promoter activity (22). Hence, an enhanced oxidative stress load may increase antigenic load, potentially driving anti- β_2 GPI production in autoimmunity-prone subjects and lowering the threshold for a clinical event. This hypothesis supports a rationale as to why SLE in particular is associated with anti- β_2 GPI antibodies, given that this condition is characterized by a propensity toward autoreactivity, B cell hyperactivity, and oxidative stress (23,24).

It was recently shown that β_2 GPI with free thiols protects endothelial cells against oxidative stress-induced cell injury, whereas oxidized β_2 GPI (which lacks free thiols) has no such protective effect (13). Given the present finding that a significant proportion of circulating β_2 GPI is in this protective reduced form in healthy individuals, it may be reasonable to hypothesize that the relative abundance of oxidized β_2 GPI in APS lowers the threshold for development of vascular thrombosis. If this hypothesis is correct, then one would expect elevated levels of oxidized β_2 GPI to represent an independent risk factor for thrombosis. Analysis of posttranslational modifications of β_2 GPI on patient samples collected prospectively and subsequent determination of the presence or absence of a thrombotic event would allow for predictive calculations that could be used to test such a hypothesis.

With the development of novel assays to detect and quantify plasma β_2 GPI-related redox changes, it is expected that stratification of anti- β_2 GPI antibody-positive individuals for thrombotic risk according to the levels of total, reduced, and oxidized β_2 GPI may be possible, with the attendant potential opportunity for implementing medical prophylactic measures during these periods of elevated risk. Prospective longitudinal studies aimed at validating the predictive and diagnostic role of such an approach are needed.

ACKNOWLEDGMENTS

We would like to thank Dr. Inger Schousboe (University of Copenhagen, Copenhagen, Denmark) for kindly donating purified native β_2 GPI. Also thanks to Professor Marissa Lassere (St. George Hospital, University of New South Wales) for initial advice regarding statistical analyses.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Krilis had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Ioannou, Zhang, Lau, Vlachoyiannopoulos, Moutsopoulos, Atsumi, Giannakopoulos, Krilis.

Acquisition of data. Ioannou, Zhang, M. Qi, Gao, J. C. Qi, Lau, Sturgess, Vlachoyiannopoulos, Moutsopoulos, Rahman, Pericleous, Atsumi, Giannakopoulos, Krilis.

Analysis and interpretation of data. Ioannou, Zhang, M. Qi, Gao, J. C. Qi, Yu, Lau, Vlachoyiannopoulos, Moutsopoulos, Rahman, Atsumi, Koike, Heritier, Giannakopoulos, Krilis.

REFERENCES

- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006;4:295–306.
- McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β_2 -glycoprotein I (apolipoprotein H). *Proc Natl Acad Sci U S A* 1990;87:4120–4.
- Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, et al. Anti- β_2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. *J Thromb Haemost* 2007;5:2421–8.
- Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. *Lancet Neurol* 2009;8:998–1005.
- Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. *Blood* 2007;109:422–30.
- Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. *Ann Rheum Dis* 2009;68:1428–32.
- Miyakis S, Giannakopoulos B, Krilis SA. β_2 glycoprotein I—function in health and disease. *Thromb Res* 2004;114:335–46.
- Shi T, Iverson GM, Qi JC, Cockerill KA, Linnik MD, Konecny P, et al. β_2 -glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped β_2 -glycoprotein I. *Proc Natl Acad Sci U S A* 2004;101:3939–44.
- Yu P, Passam FH, Yu DM, Denyer G, Krilis S. β_2 -glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. *J Thromb Haemost* 2008;6:1215–23.
- Maiti SN, Balasubramanian K, Ramoth JA, Schroit AJ. β_2 -glycoprotein I-dependent macrophage uptake of apoptotic cells: binding to lipoprotein receptor-related protein receptor family members. *J Biol Chem* 2008;283:3761–6.
- Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten

- A, Simmelink MJ, et al. Adhesion mechanism of human β_2 -glycoprotein I to phospholipids based on its crystal structure. *EMBO J* 1999;18:5166-74.
12. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, et al. Crystal structure of human β_2 -glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. *EMBO J* 1999;18:6228-39.
 13. Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, et al. Naturally occurring free thiols within β_2 -glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells and regulation of oxidative stress induced cell injury. *Blood* 2010;116:1961-70.
 14. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong J, Tanaka K, et al. β_2 glycoprotein I is a substrate of thiol oxidoreductases. *Blood* 2010;116:1995-7.
 15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
 16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.
 17. Sheng Y, Hanly JG, Reddel SW, Kouts S, Guerin J, Koike T, et al. Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding β_2 -glycoprotein I and prothrombin. *Clin Exp Immunol* 2001;124:502-8.
 18. Kouts S, Wang MX, Adelstein S, Krilis SA. Immunization of a rabbit with β_2 -glycoprotein I induces charge-dependent crossreactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies. *J Immunol* 1995;155:958-66.
 19. Vlachoyiannopoulos PG, Krilis SA, Hunt JE, Manoussakis MN, Moutsopoulos HM. Patients with anticardiolipin antibodies with and without antiphospholipid syndrome: their clinical features and β_2 -glycoprotein-I plasma levels. *Eur J Clin Invest* 1992;22:482-7.
 20. De Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. β_2 -glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. *Blood* 2004;104:3598-602.
 21. Morris JM, Gopaul NK, Endresen MJ, Knight M, Linton EA, Dhir S, et al. Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. *Br J Obstet Gynaecol* 1998;105:1195-9.
 22. Chiu WC, Chen CJ, Lee TS, Chen ZJ, Ke PH, Chiang AN. Oxidative stress enhances AP-1 and NF- κ B-mediated regulation of β_2 -glycoprotein I gene expression in hepatoma cells. *J Cell Biochem* 2010;111:988-98.
 23. Rahman A, Isenberg DA. Systemic lupus erythematosus. *N Engl J Med* 2008;358:929-39.
 24. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. *Arthritis Rheum* 2010;62:2064-72.

Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome

Olga Amengual, Tatsuya Atsumi* and Takao Koike

Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Abstract: The antiphospholipid syndrome (APS) is an autoimmune disease in which recurrent vascular thrombosis, pregnancy morbidity or a combination of these events is associated with the persistent presence of circulating antiphospholipid antibodies (aPL). Evidence shows that the dominant antigenic targets for aPL in APS are phospholipid-binding plasma proteins such as β 2glycoprotein I and prothrombin.

The pathogenic role of aPL in thrombosis is widely accepted but the mechanisms by which these antibodies mediate disease are only partially understood. aPL may affect the normal procoagulant and anticoagulant reactions occurring on cell surface, and also may interact with certain cells, altering the expression and secretion of procoagulant substances.

The intracellular signal transduction triggered by aPL has been a focus of intensive research and the p38 mitogen activated protein kinase (MAPK) pathway has been revealed as a major player in the aPL-mediated cell activation. In addition, some candidates as cell-receptor for phospholipid-binding plasma proteins have been identified. The recognition of the intracellular signaling triggered by aPL is a step forward in the design of new modalities of targeted therapies for thrombosis in APS including specific inhibitors of MAPK pathway or antagonists of the putative receptors. Furthermore, novel findings regarding the role of aPL in T-cells responses mark new advances in the understanding of the immunological reactions in APS and open new insights into possible therapeutic approaches to APS.

In this article, we review the pathophysiological mechanisms of thrombosis and the specific new targeted therapies for the treatment in APS.

Keywords: Antiphospholipid antibodies, p38MAPK, β 2GPI, prothrombin, tissue factor.

INTRODUCTION

The antiphospholipid syndrome (APS), also known as Hughes' syndrome, is an autoimmune and multisystem disorder characterized by vascular thrombosis and pregnancy morbidity in association with the persistent laboratory evidence for antiphospholipid antibodies (aPL) [1, 2].

The APS was initially characterized in patients with systemic lupus erythematosus (SLE), but it can also occur in the absence of autoimmune diseases [3]. The most common clinical manifestations of the APS are venous thrombosis, particularly deep vein thrombosis in the lower extremities, followed by cerebral infarction or transient ischemic attacks [4]. Antiphospholipid syndrome represents one of the major risk factors for ischaemic cerebral events in young people without congenital atherosclerotic diseases [5].

Recurrent fetal losses in APS may happen at any stage of pregnancy, but are strikingly frequent during the second or third trimester. APS patients are susceptible to early onset of pregnancy complications such as severe pre-eclampsia and HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) [2, 4, 6]. Moreover, aPL may be found in up to 20% of woman with recurrent pregnancy losses [7].

Other aPL-related abnormalities include non-thrombotic neurological syndromes, psychiatric manifestations, skin ulcers, livedo reticularis, haemolytic anemia, thrombocytopenia, nephropathy, pulmonary hypertension and heart valve abnormalities [4].

A minority of patients with APS develops an accelerated form of this syndrome with life-threatening multiple organ thromboses, severe thrombocytopenia and adult respiratory distress syndrome recognized as catastrophic APS [8].

The original concept of aPL considers that those antibodies were directed against anionic phospholipids. However, it is now well established that aPL include a heterogeneous group of circulating immunoglobulins and that proteins that bind to anionic phospholipids, such as beta2 Glycoprotein I (β 2GPI) and prothrombin, are the main antigenic targets recognized by aPL in patients with APS [9-12].

aPL can be broadly categorized into those antibodies that bind to immobilized anionic phospholipid in solid phase enzyme linked immunosorbent assay (ELISA), known as anti-cardiolipin antibodies (aCL) [13], or those that prolong phospholipid-dependent coagulation assays, called lupus anticoagulant (LA) [14]. New assays have been developed for the detection of antibodies targeting phospholipid-binding protein complexes, comprising anti β 2GPI antibodies [15-17] and antiprothrombin antibodies [18-21].

*Address correspondence to this author at the Department of Medicine II, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan; Tel: + 81-11-706-5915; Fax: + 81-11-706-7710; E-mail: at3tat@med.hokudai.ac.jp

In 1998, an international consensus on classification criteria for definite APS was met in Sapporo; the criteria were thus called Sapporo criteria [2], and they were revised in 2006 [22]. The diagnosis of APS is made when at least 1 of the 2 clinical criteria (vascular thrombosis or pregnancy morbidity) occurs in a patient whose laboratory tests for aPL are positive (Table 1).

Table 1. Revised Classification Criteria for the Antiphospholipid Syndrome [2]

<p>Clinical Criteria</p> <p>1. Vascular thrombosis</p> <p>≥ 1 clinical episodes of arterial, venous, or small vessel thrombosis, in any tissue or organ confirmed by objective validated criteria by imaging studies or histopathology in the absence of significant evidence of inflammation in the vessel wall.</p> <p>2. Pregnancy morbidity</p> <p>≥ 1 unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation, or,</p> <p>≥ 1 premature births of a morphologically normal neonate before the 34th week of gestation due to eclampsia, severe pre-eclampsia or placental insufficiency, or</p> <p>≥ 3 unexplained consecutive spontaneous abortions before the 10th week of gestation (maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded).</p> <p>Laboratory Criteria</p> <p>a) LA present in plasma, on ≥ 2 occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Haemostasis [14, 23]</p> <p>b) IgG and/or IgM aCL present in medium or high titer in serum or plasma, on ≥ 2 occasions at least 12 weeks apart, measured by a standardized ELISA [24]</p> <p>c) IgG and/or IgM antiβ2glycoprotein I antibodies present in titer >99th percentile, in serum or plasma, on ≥ 2 occasions at least 12 weeks apart, measured by a standardized ELISA [25]</p>

Antiphospholipid syndrome is present if at least 1 of the clinical criteria and 1 of the laboratory criteria are met. ELISA: enzyme-linked immunosorbent assay.

Numerous mechanisms have been proposed to explain the pathogenicity of aPL in APS as shown in Table 2.

Table 2. Proposed Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis

<p>1. Interference with the coagulation pathway:</p> <p>a) Protein C pathway:</p> <p>b) Contact activation pathway</p> <p>c) β2GPI-thrombin interaction</p> <p>d) Protein Z pathway</p> <p>2. Disruption of fibrinolysis</p> <p>3. Cell interaction:</p> <p>a) Induction of pro-coagulant activity on endothelial cell and monocytes</p> <p>b) Pro-coagulant effects on platelets</p> <p>c) Release of membrane-bound microparticles</p> <p>4. Complement activation</p>
--

Genetic and acquired factors may trigger to develop thrombosis in susceptible individuals. However, it is yet not possible to assert whether a dominant mechanism is respon-

sible for some specific clinical manifestations of APS or whether different antibodies acting together predispose to thrombosis [26].

Primary and secondary thrombosis prevention is crucial in APS, but treatment is conditioned by the lack of appropriate studies due to the poor laboratory standardization.

This article summarizes some of the major pathophysiological mechanisms that may contribute to the APS manifestations. In addition, the current modalities of treatment and the potentially specific new targeted therapies for APS are reviewed.

PATHOPHYSIOLOGY OF APS

Multifactorial thrombotic mechanisms, such as the inhibition of the natural anticoagulant systems, the impairment of fibrinolysis and the direct effect of aPL on cell functions, are involved in the development of thrombosis in APS. Evidence suggests that complement activation is also required for aPL-mediated tissue injury [27].

1. Interference with the Coagulation Pathway

The coagulation system is an amplification cascade of enzymatic reactions resulting in thrombin formation. Thrombin has several prothrombotic properties and also activates protein C. Protein C is a major constituent of the anticoagulant system and its impairment may lead to blood clot. Thrombin triggers the protein C system by binding to thrombomodulin and initiating rapid protein C activation. Activated protein C complexes with protein S on the surface of either platelets or endothelial cells. These complexes proteolytically catalyze the inactivation of activated factors V and VIII. Because both protein C and protein S are phospholipid-binding plasma proteins, this system could be one of the most likely to be involved in development of thrombosis in the APS.

aPL may interfere with the protein C pathway in different ways. aPL have been reported to inhibit both the activation of protein C by the thrombin-thrombomodulin complex [28] and the activated protein C-catalysed inactivation of activated factor V [29-33]. The inhibitory effect of IgG purified from patients with aPL on activated factor V inactivation mediated by activated protein C was subsequently confirmed [30, 34]. Rabbit polyclonal [35] and human monoclonal antiβ2GPI antibodies inhibit activated protein C function [32]. Moreover, aCL bound to protein C in the presence of both phospholipids and β2GPI, and binding activities strongly correlated with antiβ2GPI antibody titers, indicating that protein C might be a target of aCL resulting in the protein C dysfunction [36]. Izumi *et al.* [37] confirmed the inhibitory effect of antiβ2GPI antibodies purified from APS patients on the anticoagulant activity of activated protein C. Those authors demonstrated that binding of β2GPI to the phospholipid membrane surface is necessary to express this inhibitory activity

Most prothrombin-antiprothrombin immune complexes may predispose to thrombosis by interfering with the inactivation of activated factor V by the activated protein C in the presence of protein S [38]. This inhibitory effect of anti-

prothrombin antibodies on activity of the activated protein C was also demonstrated in the absence of protein S [39].

Finally, aPL may alter the effect of protein S in the protein C pathway. Decreased levels of protein S have been detected in plasma from APS patients [40, 41]. Some of the IgG that inhibit activated factor V degradation were directed not only to phospholipid-bound protein C but also to phospholipid-bound protein S [42].

There are some conflicting data between studies regarding the involvement of protein C pathway in the pathophysiology of APS, probably related to the heterogeneity of aPL found in patients with APS. The thrombotic predisposition for individual patient will vary depending on antibody-dependent and independent variables.

Other possible mechanism of thrombosis in APS is the interference of aPL with the contact pathway of coagulation. This coagulation pathway is initiated by the activation of factor XII by negative charged surfaces, then activated factor XII cleaves factor XI to activated factor XI in the presence of high-molecular kininogen and prekallikrein. β 2GPI inhibited the phospholipid-mediated autoactivation of factor XII and the contact activation pathway of coagulation [43]. Further, β 2GPI directly binds to factor XI and inhibits activation of factor XI by thrombin and activated factor XII; this inhibition attenuates thrombin generation [44]. Monoclonal anti β 2GPI antibodies enhanced the inhibition of factor XI activation by β 2GPI and thrombin complex [45].

Thrombin, the final enzyme in the coagulation cascade, is generated from its inactive precursor prothrombin by activated factor X as part of the prothrombinase complex, on the surface of activated cells. Apart of the prothrombotic properties, thrombin is also involved in the regulation of many biological functions *in vivo*. β 2GPI participates in thrombin generation as demonstrated by the significant reduction of *in vitro* ability to generate thrombin observed in plasma from β 2GPI-null mice [46]. β 2GPI directly binds to thrombin [45], indicating that β 2GPI-thrombin interaction may interfere not only with the coagulation system but also with many of the biological functions in which thrombin participates.

The inhibition of protein Z, has been proposed as an additional thrombotic mechanism in APS. Protein Z is a vitamin K dependent protein that functions as a natural anticoagulant. Protein Z serves as cofactor for the inactivation of activated factor X by the plasma protein Z-dependent protease inhibitor [47]. Reduced plasma levels of protein Z were detected in patients with aPL [48, 49] and were associated with thrombosis [50]. In the presence of β 2GPI, aPL greatly impair the inhibition of activated factor X by protein Z-dependent protease inhibitor [51].

2. Disruption of Fibrinolysis

The fibrinolytic system involves the formation of plasmin from plasminogen by the tissue-type plasminogen activator (tPA); this, in turn, degrades fibrin into fibrin degradation products. The regulation of plasmin generation and activity is highly important to maintain the homeostatic balance *in vivo*. Inhibition of the fibrinolytic system may occur at the level of plasminogen activators by specific plasminogen activator inhibitors (PAI-1 and PAI-2) or at the levels of plas-

min by α 2-antiplasmin. Endothelial cells when activated, secrete the PAI-1 to regulate fibrinolysis by blocking tPA activity.

The effect of aPL in the fibrinolytic system has been investigated with controversial results probably due to the heterogeneity of the cohorts. Several other reports pointed toward a hypofibrinolytic state in APS characterized by elevated PAI-1 indicating a perturbation of endothelial cells with consequent fibrinolytic impairment [52-54]. Patients with connective tissue diseases, including APS, might have a hypofibrinolytic condition related to high PAI-1 levels [55]. Ames *et al.* [40] showed up-regulation of PAI-1 in females with primary APS. They further showed a reduction in tPA release by endothelial cell stimulation, suggesting that tPA/PAI-1 balance was decisive to develop thrombosis in some APS patients. Monoclonal aCL appear to inhibit fibrinolysis by a β 2GPI-dependent increase in PAI-1 activity [56]. Monoclonal anti β 2GPI antibodies significantly suppressed the intrinsic fibrinolytic activity *in vitro*. The inhibition was attributed to a reduced contact activation reaction started by activated factor XII [57]. Impaired activated factor XII-dependent activation of fibrinolysis was observed in pregnant woman with APS which developed late-pregnancy complications [58]. Antibodies against the catalytic domain of tPA were found in patients with APS and might represent a cause of hypofibrinolysis [59].

On the other hand, aPL might directly inhibit plasmin activity. High affinity antiplasmin antibodies that inhibit degradation of fibrin have been detected in patients with APS [60]. Moreover, IgG from APS patients significantly retard fibrin dissolution by plasmin [61].

Finally, the influence of lipoprotein a (Lp(a)) in the fibrinolytic system has been evaluated. Lp(a) inhibits fibrinolysis by acting as an uncompetitive inhibitor of tPA, but also by increasing PAI-1 expression in endothelial cells [62-65]. This behaviour confers a prothrombotic potential to Lp(a). Plasma levels of Lp(a) were found to be significantly increased in patients with APS [64, 65]. Further, patients with maximal elevation of Lp(a) showed a reduced fibrinolytic activity, estimated by low D-Dimer and high PAI-1 levels [64].

3. aPL and Cell Interaction

Damaged and/or activated endothelial cells or monocytes are predominant targets of aPL. Cultured endothelial cells incubated with aPL expressed high levels of adhesion molecules [66, 67], tissue factor (TF) [68-71] and endothelin-1 [72]. This effect is mediated by β 2GPI and cell surface receptors and may promote inflammation and thrombosis [73, 74]. Prothrombin also binds to endothelial cells, and this binding was enhanced by a human monoclonal IgG anti-prothrombin antibody, IS6. IS6 up-regulates expression of TF and E-selectin on endothelial cells [75].

The production of microparticles is a hallmark of cell activation, and aPL stimulated the release of microparticles from endothelial cells [76]. Finally, some aPL that recognize annexin-V are able to induce apoptosis on endothelial cells [77].

Platelets are prone to agglutinate and aggregate after exposure to aPL [78], and circulating activated platelets have been found in patients with APS [79, 80]. β 2GPI binds to surface membranes of activated platelets and inhibits the generation of activated factor X [81-83]. Anti β 2GPI antibodies interfered with this inhibition [82].

The cell activation mediated by aPL requires the interaction between phospholipid-binding plasma protein complexes and probably a specific cell receptors. A number of potential receptors for the binding of β 2GPI to cellular membranes have been identified including annexin A2, apolipoprotein E receptor 2 (ApoER2'), low-density-lipoprotein receptor-related protein, megalin, toll like receptor (TLR) 2, TLR 4, the very-low-density-lipoprotein receptor and P-selectin glycoprotein ligand-1. β 2GPI directly binds to glycoprotein Ib α subunit of the platelet adhesion receptor glycoprotein (GP)Ib/IX/V and to the platelet factor 4 [84-92]. It seems very unlikely that so many different receptors will be substantial involved in the pathophysiology of thrombosis in APS. Further studies are necessary to clarify the biological and pathological roles of those receptors in the aPL-mediated cell activation in patients with APS.

The signal transduction mechanisms involved in aPL mediated cell activation have been the centre of interest for many researchers. The adapter molecule myeloid differentiation protein (MyD88)-dependent signaling pathway and the nuclear factor kappa B (NF κ B) have been involved in endothelial cell activation by aPL [86, 93-95]. The p38 mitogen-activated protein kinase (MAPK) pathway is an important component of intracellular signaling cascades that initiate various inflammatory responses. The p38MAPK pathway has a crucial role in mediating the effects of aPL on cell activation. Monoclonal anti β 2GPI antibodies from APS patients induce phosphorylation of p38MAPK, a locational shift of NF κ B into the nucleus and up-regulation of TF on monocytes [96]. The importance of the p38 MAPK pathway in cell activation was also reported in platelets [97], and endothelial cells [98]. Activation of p38 MAPK pathway increases activities of cytokines such as tumor necrosis (TNF) α and interleukin (IL)-1 β and macrophage inflammatory cytokine 3 β [96, 99, 100].

4. Complement Activation and aPL

Complement activation was determined to be relevant to the pathophysiology of APS, especially with regard to pregnancy morbidity [101]. Placenta trophoblast cells are targeted by phospholipid-binding plasma protein-aPL complexes, leading to the activation of the complement cascade through the classical pathway. Then generated component complement C5a, through the alternative pathway, recruits and activates monocytes and polymorphonuclear leukocytes, stimulating the release of mediators of inflammation, which ultimately results in fetal injury [102]. In patients with unexplained pregnancy loss, elevated levels of complement components C3 and C4 predicted subsequent miscarriages [103]. Moreover, patients with cerebral ischemic events had higher levels of complement activation products compared to patients with non-APS-related cerebral ischemia [104].

We [105] analyzed the profile of complement activation in patients with primary APS and found that hypocomple-

mentemia related to complement over-activation is common in those patients. The serum complement levels correlated with LA activity and plasma levels of TNF α , implying that complement activation induced by aPL may be one of the responsible mechanisms of the thrombotic state in APS

The IgG isotype of aPL is the most frequently found in patients with APS, and the IgG2 subclass is the most prevalent [106, 107]. IgG2 and IgG4 subclasses have a relatively weak ability to fix the complement *via* the classical pathways: thus, other additional mechanisms may be involved in the enhancement of complement activation in patients with aPL.

TREATMENT OF APS

Strategies to prevent thrombosis should be part of the management of patients with APS. Smoking cessation, the use of protective medications and stratification of the risk of thrombosis, are important aspects of the care of those patients. The estrogen component of oral contraceptive increases blood coagulability and the risk of thrombosis in the general population. There are case reports of patients with APS developing thrombosis on contraception, thus oral contraceptives are generally contraindicated in aPL-positive patients. Contraceptives containing only progesterone do not increase the risk of venous thromboembolism [108] and they can be considered in patients with aPL. However, there are no controlled studies supporting this approach [109].

The current treatment of APS involves antithrombotic agents to control and prevent recurrent thrombosis. Therapy to inhibit the immunological or inflammatory mediators of the disease has been used in some life-threatening cases of APS without promising outcomes.

The great advances in the understanding of the molecular basis of aPL-mediated pathogenicity over the last half century have led to the development of targeted biological therapies. However, the optimum therapy for APS has not been yet reached. Current and potential therapeutic options for APS are summarized in Table 3.

THERAPIES CURRENTLY USED FOR APS

Anticoagulation with therapeutic heparin followed by life-long secondary thromboprophylaxis with oral vitamin K antagonist is the current advised treatment of thrombosis in APS [110]. However, there is not yet consensus on the optimal intensity of anticoagulation with oral vitamin K antagonists. Low dose of aspirin (LDA) is often added to the anticoagulation therapy in patients with arterial events [111].

Prevention of fetal loss and maternal thrombotic complications during pregnancy include the combination of LDA and heparin. Both heparin and low molecular weight heparin (LMWH) do not cross the placental barrier but the latter is preferable during pregnancy because of the lower risk for heparin-induced thrombocytopenia and osteoporosis. If this regimen is not effective, the addition of intravenous immunoglobulins (IVIG) may be effective to improve fetal outcome in some cases [112, 113]. IVIG would act by favoring the clearance of pathological immunoglobulins and blocking the pathological autoantibodies due to the effect of anti-idiotypic antibodies.

Table 3. Therapeutic Options in the Treatment of APS

<p>I. Current treatment</p> <ul style="list-style-type: none"> • Anticoagulants: Heparin, LMWH and warfarin • Low dose aspirin • IVIG in pregnancy morbidity refractory to aspirin and heparin combination • Antiplatelet agents rather than aspirin • Corticosteroids* • Plasma exchange* • Vasodilators* <p>II. Drugs currently used for other diseases with potential to be effective in APS</p> <ul style="list-style-type: none"> • Hydroxychloroquine • Statins • Angiotensin-converting enzyme inhibitors • Recombinant human activated protein C • Recombinant human thrombomodulin • New anticoagulants • Tumor necrosis alpha antagonists • Anti CD20⁺ B cells antibody (Rituximab)

LMWH: low molecular weight heparin, IVIG: intravenous immunoglobulins.

*Those drugs are currently used in case of catastrophic APS or refractory APS.

Aspirin showed a prophylactic role for primary prevention of thrombosis in aPL-positive patients [114], but those results are not supported by data from a prospective controlled study [115]. In addition, long-term oral anticoagulation at a relative high intensity is associated with an increase risk of bleeding and under-anticoagulation with a risk of recurrences [110]. Given these concerns, new, safer and more-efficient modalities for prevention and treatment of thrombosis are needed.

Antiplatelet agents, other than aspirin, such as dipyridamole, ticlopidine, clopidogrel bisulfate and cilostazol had been empirically used in selected patients with APS and may represent an alternative to warfarin to prevent further aPL-related arterial thrombosis. Those drugs could offer benefit in short-term secondary prevention after non-cardioembolic strokes or transitory ischemic attacks [116]. Dilazep and dipyridamole block the monocyte-TF expression induced by purified IgG from APS patients [117], but there are no clinical trials evaluating their efficacy on primary or secondary thrombosis prevention in patients with aPL.

In case of a life-threatening condition such as catastrophic APS, the combination of intravenous anticoagulation, corticosteroids and IVIG or plasma exchange with fresh frozen plasma showed the highest survival rates [118]. Plasma exchange can remove, not only pathologic aPL, but also activated complement and other inflammation mediators. The fresh frozen plasma provides natural intact anticoagulants, mainly antithrombin and protein C.

Rituximab, a monoclonal antibody that selectively depletes CD20⁺ B cells, has been successfully employed in a small number of patients with resistant APS including catastrophic APS. This biological reagent reduces the aPL titers, but its effect on the prevention of thrombotic recurrence has not been proven [119-121].

Prostacyclin and prostaglandin E1 treatment result in vasodilatation and inhibition of platelet aggregation. The use of those drugs in patients with aPL is anecdotal and further studies are necessary to evaluate the effectiveness and the risk of re-thrombosis [122].

POTENTIAL THERAPIES FOR APS

In this section, some drugs with anti-thrombotic and immunomodulatory effects currently used to treat other disease are discussed. Those agents potentially can be used as additional drugs for the treatment and the prevention of aPL-related complications.

1. Hydroxychloroquine

Hydroxychloroquine is considered an integral component of the treatment of APS in patients with concomitant SLE, and has been associated with a decreased thrombotic risk in aPL-positive SLE patients [123]. In addition to anti-inflammatory and immunomodulatory effects, hydroxychloroquine has anticoagulant potential which may be due to the ability to inhibit platelet aggregation and the release of arachidonic acid from stimulated platelets. Hydroxychloroquine repressed aPL-induced platelet activation *in vitro* [124], and reduced both thrombus size and time of thrombus persistence in an APS mouse model [125]. This drug may be of benefit in the management of patients with aPL, but its effectiveness for thromboprophylaxis should be determined by controlled studies [126].

2. Statins

Statins are cholesterol-lowering drugs that act as competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) which catalyzes the cholesterol synthesis in the mevalonate pathway. Beside cholesterol lowering activity, statins have anti-inflammatory effects modifying the function of endothelial cells, platelets and monocytes/macrophages. Statins down-regulated the production of cytokines in endothelial cells, interfered with leukocyte-endothelial interaction, inhibited TF expression by mononuclear cells, increased fibrinolytic activity and hampered platelet function [127]. Fluvastatin interfered with the expression of adhesion molecules and IL-6, and reversed the up-regulation of TF mediated by aPL in endothelial cells [93, 128, 129]. Moreover, in aPL-treated mice, fluvastatin diminished thrombus size [130].

Statins are widely used drugs known to be effective for the prevention and treatment of atherosclerosis and cardiovascular diseases [131], but still there are not data regarding its potential on thrombosis prevention in aPL-positive patients. In an animal model of mice treated with aPL, simvastatin and pravastatin decreased the expression of TF and protease-activator receptor 2 on neutrophils and prevented fetal loss, suggesting that statins may be a favorable treatment in woman with aPL-induced pregnancy complications [132].

3. Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE) inhibitors have beneficial effects in vascular diseases and significantly improved survival in patients with atherosclerosis. ACE inhibitors reduced TF levels and TF expression on monocytes in patients with myocardial infarction [133, 134]. Experimental studies demonstrated the inhibitory effect of ACE inhibitors on NF κ B with consecutive down-regulation of TF [135-137]. Therefore, ACE inhibitors have the potential to reduce TF expression. Recently, angiotensin receptor blockers (ARB) are taking the place of ACE inhibitors as antihypertensive drugs. Clinical trials for ACE inhibitors or ARB in aPL-positive patients are warranted.

4. Recombinant Human Activated Protein C and Recombinant Human Thrombomodulin

Activated protein C is one of the major regulators of thrombin generation, and also possesses anti-thrombotic and anti-inflammatory properties reducing cytokine production and expression of adhesion molecules on endothelial cells [138]. Recombinant human activated protein C (Drotrecogin alpha) has been demonstrated beneficial in patients with severe sepsis where microvascular thrombi are the major feature. Administration of recombinant human activated protein C may restore the dysfunctional anticoagulant mechanisms, prevent amplification and propagation of thrombin generation and formation of microvascular thrombosis, and may simultaneously modulate the systemic pro-inflammatory response [139].

Thrombomodulin, a receptor of thrombin and thrombin-thrombomodulin complex, is a natural activator of protein C. Thrombomodulin works as anticoagulant only when thrombin is excessive. Therefore, thrombomodulin is the ideal anticoagulant with minimal risk of bleeding complications. The use of recombinant human soluble thrombomodulin has been approved for the treatment of disseminated intravascular coagulation [140].

Impairment of protein system C by aPL have an important role in the pathogenesis of APS. Those drugs are promising for APS when infection events trigger the development of thrombosis.

5. New Anticoagulants

Anticoagulants such as warfarin and heparin act on a number of targets, whereas the newer anticoagulants have been designed to selectively inhibit one specific target in the coagulation system. Therefore, those new agents might be more effective and safer than current anticoagulants with a promising role in the management of APS. Some of these emerging anticoagulants agents are already approved and used in clinical practice but others are still in development phase.

New anticoagulants that selectively inhibit thrombin either directly through binding to thrombin and inhibiting its interaction, or indirectly through antithrombin, have been developed. Direct thrombin inhibitors include lepirudin and argatroban, approved for patients with heparin-induced thrombocytopenia [141]. Bivalirudin was approved for percutaneous coronary interventions in patients with acute coro-

nary syndrome [142]. Ximelagatran, an oral direct thrombin inhibitor, showed very promising data and entered in late phase clinical development. However, there were many concerns in safety, especially with liver toxicity. In 2004, the Food and Drug Administration rejected the drug license in the United States, and in 2006 it was finally withdrawn from the world market [143].

Fondaparinux is a synthetic pentasaccharide, which binds to antithrombin thereby indirectly inhibiting activated factor X and thrombin generation. This drug has little effect on platelet aggregation. Fondaparinux is subcutaneously administered and has been approved for the prevention and treatment of venous thromboembolism [144].

Rivaroxaban a selective direct inhibitor of activated factor X with high oral bioavailability, and dabigatran, an oral direct thrombin inhibitor, are approved for the prevention of venous thromboembolism following orthopaedic surgery [145, 146].

Other emerging anticoagulant is recombinant nematode anticoagulant protein c2 (rNAPc2), an 85-amino acid protein that is a potent inhibitor of the activated factor VII/TF complex, the key physiological initiator of blood coagulation. Recombinant NAPc2 might be effective in thrombosis prophylaxis by attenuating the initiation and propagation of thrombin generation. This drug was effective in reducing the postoperative venous thromboembolism in patients undergoing total knee replacement [143], and suppressed thrombin generation in patients undergoing coronary angioplasty [147]. Because of its unique mechanism of inhibition of activated factor VII/TF, rNAPc2 should be considered as future therapeutic options for APS.

6. TNF α Antagonists

In an animal model of APS, TNF α was a critical mediator of aPL-induced fetal loss and was released in response to complement activation. TNF α DNA vaccination prevented clinical manifestations of experimental APS [148], and TNF α deficiency provided fetal protection in aPL-treated mice. In addition, TNF α was released from monocytes treated with anti β 2GPI antibodies [100]. Those observations identify TNF α as a potential target for the therapy of the pregnancy complications of APS. However, TNF α blockade does not completely protect pregnancy problems, thus it is likely that other effector pathways contribute to the fetal death [149].

On the other hand, TNF α blockers therapy has been associated with increase in the frequency of aCL or anti β 2GPI antibody positivity [150-152]. No consensus exists on the merit of TNF blockade in patients with APS.

NEW TARGETED TREATMENTS FOR APS

New targeted therapies with potential to be effective for the management of APS are reviewed and summarized in Table 4.

1. Inhibitors of p38MAPK and NF κ B

The p38MAPK pathway is essential in mediating the effect of aPL. Both p38MAPK phosphorylation and NF κ B

translocation are required for aPL-mediated TF up-regulation on endothelial cells and monocytes. Treatment with a specific p38MAPK inhibitor, SB203580, inhibits platelet aggregation and thromboxane A₂ production induced by aPL [97]. Moreover, SB203580 reversed the effect of aPL on TF expression and IL-6 and IL-8 up-regulation [98].

Table 4. New Therapeutic Strategies for APS Treatment

I. Specific targeted therapies	
▪	p38MAPK pathway and NFκB inhibitors
▪	Tissue Factor inhibitors
▪	Platelet activation inhibitors: - Receptor specific antagonists - Thromboxane A ₂ inhibitors
▪	Specific complement inhibitors
II. Immunomodulation	
▪	Bone marrow transplantation
▪	T cell blockage
▪	Specific B cell molecular targeting

p38 MAPK: p38 mitogen activated protein kinase, NFκB: nuclear factor kappa B.

The specific NFκB-inhibitor MG132 significantly reduced up-regulation of TF and enhancement of thrombosis mediated by aPL *in vivo* [153]. The activation of NFκB by aPL was also inhibited by SN50, a specific inhibitor of NFκB translocation [154]. Those findings represent innovative modalities of targeted therapies for the treatment of thrombosis in APS, but there is still many questions which need to be answered such a long-term effect and safety.

2. Inhibitors of Tissue Factor expression

Tissue factor is a transmembrane protein normally found in sub-endothelial structures of blood vessels and expressed upon activation on the surface of monocytes, endothelial cells and smooth muscle cells. Following its exposure to blood, TF binds specifically to activated factor VII. The formation of the activated factor VII/TF complex is critical for the initiation of the proteolytic reactions leading to the generation of thrombin, and eventually to clot formation. [155]. Increased TF expression is widely recognized as one the aPL-mediated mechanism of hypercoagulability [69, 70, 156, 157].

TF is one the major potential target for pharmacological interventions and blockage of TF activity is one of the promising therapies in APS. Therapeutic approaches targeting TF include dilazep dipyrindamole, pentoxifyllines, defibrotide and ACE inhibitors such as captopril [117, 133, 158]. Those agents suppressed the monocytes TF expression induced by aPL or lipopolysaccharide. However, there are no clinical studies on patients with APS

3. Inhibitors of Platelet Activation

a) Receptor Specific Antagonists

Antiphospholipid antibodies can cause platelet activation and aggregation in the presence of low concentration of

platelet agonists [159]. Also, aPL can enhance the expression of platelet membrane GP particularly GPIIb/IIIa, a receptor involved in platelet aggregation [124]. Infusions of a GPIIb/IIIa antagonistic monoclonal antibody (IB5) abrogated the aPL-induced thrombosis *in vivo*. Further, aPL-mediated thrombosis is not observed in GPIIb/IIIa deficient mouse [127]. Double heterozygosity polymorphisms for platelet GPIa/IIa and GPIIb/IIIa increase the risk of arterial thrombosis in patients with APS [160].

Platelet GPIIb/IIIa antagonists abciximab, tirofiban and eptifibatide, have been used in the treatment of myocardial infarction and acute ischemic stroke, showing its efficacy in acute coronary syndrome in combination with other therapies. However, results have been less consistent in ischemic stroke. While phase I and II trials of abciximab as the sole agent were promising, the phase II trial was abandoned because of unfavorable benefit to risk ratio. Presumably, the benefit of these drugs for patients with APS is limited [161].

The effects of aPL in GPIIb/IIIa expression are significantly reduced by hydroxychloroquine and this inhibitory effect may be one of the mechanisms by which this drug prevent thrombosis [124].

The blockage of the platelet receptor ApoER2' using a receptor-associated protein (RAP) abrogated the increased adhesion of platelet to collagen induce by β2GPI-antiβ2GPI antibody complex [162]. Thus, inhibition of ApoER2' might contribute to the prevention of thrombosis in APS patients.

Recently, the binding of β2GPI to platelet factor 4 has been reported [163]. β2GPI forms stable complexes with platelet factor 4, leading to the stabilization of β2GPI dimeric structure that facilitates the antibody recognition. The β2GPI-platelet factor 4 complex is strongly recognized by serum of patients with APS. Moreover, platelets may be activated by β2GPI-antiβ2GPI antibody-platelet factor 4 or β2GPI-platelet factor 4 complexes. Almost every cell type can be a source of platelet factor 4 especially under some stimulation. Both, β2GPI I and platelet factor 4 are abundant in plasma, thus the preformed β2GPI-platelet factor 4 complexes may prime several pro-coagulants cells culminating in coagulation. The blockage of the interaction between β2GPI-platelet factor 4 might be a novel approach in the targeted therapies in APS.

The other putative receptor proteins described before may be potential target therapies to reduce the aPL-mediated effects, but there are not yet data available to suppose this therapeutic strategy.

b) Thromboxane A₂ Inhibitors

Thromboxane A₂ is one of the most powerful agonist for platelet activation and exerts a vasoconstrictor effect by serving as agonist of the thromboxane receptor. Clinical and experimental data suggest that inhibition of thromboxane production may be effective to prevent thrombotic complication in patients with aPL. Patients with APS had elevated urinary excretion of thromboxane A₂ metabolites [80]. Pre-incubation with β2GP-aCL complexes results in production by platelets of higher levels of thromboxane B₂ which is a stable metabolite of thromboxane A₂ [164]. Indomethacin, a thromboxane A₂ inhibitor, and theophylline, a phosphodi-

esterase inhibitor, abrogated aPL-mediated thromboxane A₂ production [165, 166]. On experimental APS, a long-term actin thromboxane receptor antagonist, BMS180,201, was effective to reduce the fetal resorption rate [167]. No data exist in patients who have APS regarding thromboxane receptor antagonists.

4. Specific Complement Inhibition

Inhibition of the complement cascade *in vivo*, using the C3 convertase inhibitor complement receptor 1-related gene/protein y (Crry)-Ig, blocks aPL-mediated fetal loss [168]. In addition, C3 and C5 knock-out mice less frequently developed aPL-related complications and antiC5-antibody reverse the thrombogenic properties of aPL [169]. Finally, treatment with heparin prevented aPL-induced complement activation *in vivo and in vitro*, and protected mice from aPL-related pregnancy complications [101]. Specific complement inhibitors are attractive therapies for APS. Potential targets for the therapies are drawn in Fig. (1).

IMMUNOMODULATION

Bone marrow transplantation (BMT) is currently used for the treatment of some autoimmune diseases based on the fact that autoimmunity can be either transferred or eliminated by BMT. In APS, both transfer of APS and induction of tolerance to disease has been reported [170, 171], thus BMT may have some future application for APS. On the other hand autologous stem-cell transplanted patients with scleroderma developed APS [172].

Antigen uptake, processing and presentation are the first steps following the exposure of antigen to the immune system. If we could artificially control this procedure to reduce β2GPI-reactive CD4⁺ T cell response, the subsequent reactions, including antiβ2GPI antibody production, would not occur, thus curing the disease. Therapeutic strategies should target interrupting the continuous autoimmune loop carried out by macrophages and β2GPI-reactive CD4⁺ T cells and B cells [173, 174].




Fig. (1). Targets for novel therapies in APS.

Stimulation of procoagulant cells (monocytes or endothelial cells) by antibodies against phospholipid-binding proteins induce phosphorylation of p38MAPK which leads to the nuclear translocation of NFκB, and to the up-regulation of procoagulant substances. Specific inhibitors of p38MAPK (SB203580) or NFκB may block those processes. ACE inhibitors exert inhibitory effect on NFκB with consecutive down-regulation of TF. TF expression mediated by aPL can be abrogated by statins, and by some antiplatelet agents. aPL induce the production of cellular adhesion molecules by endothelial cells which may be reduced by statins. Finally, aPL may activate complement through the classical pathway. C3a, C5a and C5b-9 (MAC) may bind to specific receptors on endothelial cells and enhance the effects of aPL on cells. AntiC5-monooclonal antibody can reduce this binding.

aPL: antiphospholipid antibodies, PL: phospholipid, p38MAPK: p38 mitogen activated protein kinase; NFκB: nuclear factor Kappa B, ACE: angiotensin-converting enzyme, TF: tissue factor, TNFα: tumor necrosis factor alpha. PAI-1: plasminogen activator inhibitor-1, C5a R: C5a receptor, C5b R: C5b receptor, MAC: membrane attack complex.

The induction of immune tolerance at B-cell level is another future therapeutic approach for the management of APS. β 2GPI-induced oral tolerance showed immunomodulatory effect in experimental APS [175]. A β 2GPI-specific B cell toleragen, LJP 1082, was developed. This drug is a tetra-valent conjugate of recombinant human domain 1 of β 2GPI that has been shown to reduce domain 1 specific antibodies and levels of antigen-specific antibodies producing B cells [176]. Results from a phase I/II clinical trial in patients with antibody-mediated thrombosis showed that the drug was well tolerated and no differences on safety were found between patients receiving LJP1082 or placebo [177]. Further development is needed to assess the effect of this drug in the reduction of thrombotic events in APS.

CONCLUSIONS

Ongoing research focused on the thrombotic mechanisms mediated by aPL has significantly advanced the understanding of the pathophysiology of the APS. Those novel discoveries opened new insights into the management of APS leading to the investigation of specific target therapy.

Data from animal models suggested attractive and novel therapeutic approaches for the prevention and treatment of aPL-related complications. However, there is still not enough information to warrant the use of those agents in APS patients. In the coming years, studies are required to validate the data in humans and to evaluate the efficacy and security of new targeted therapies in APS.

ACKNOWLEDGEMENTS

This work was supported by the Japanese Ministry of Health, Labour and Welfare, the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japanese Society for the Promotion of Science (JSPS). Olga Amengual is granted by JSPS/MEXT (ID 0940106, Project number 21-40106).

LIST OF ABBREVIATIONS

ACE	=	Angiotensin-converting enzyme
aCL	=	Anticardiolipin antibodies
aPL	=	Antiphospholipid antibodies
ApoER2'	=	Apolipoprotein E receptor 2
APS	=	Antiphospholipid syndrome
ARB	=	Angiotensin receptor blockers
β 2GPI:	=	Beta 2Glycoprotein I
BMT	=	Bone marrow transplantation
ELISA	=	Enzyme-linked immunosorbent assay
GP	=	Glycoprotein
IL	=	Interleukin
IVIG	=	Intravenous immunoglobulins
LA	=	Lupus anticoagulant
LDA	=	Low dose of aspirin
LMWH	=	Low molecular weight heparin

Lp(a)	=	Lipoprotein a
MAPK	=	Mitogen activated protein kinase
NF κ B	=	The nuclear factor kappa B
PAI	=	Plasminogen activator inhibitor
SLE	=	Systemic lupus erythematosus
TF	=	Tissue factor
TLR	=	Toll like receptor
TNF α	=	Tumor necrosis- α
tPA	=	Tissue-type plasminogen activator

REFERENCES

- [1] Khamashta MA. Hughes Syndrome: History. In: Khamashta MA, Ed. *Hughes Syndrome: Antiphospholipid syndrome*, 2nd ed. London: Springer-Verlag 2006; pp. 3-8.
- [2] Miyakis S, Lockshin MD, Atsumi T, *et al.* International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006; 4: 295-306.
- [3] Vianna JL, Khamashta MA, Ordi-Ros J, *et al.* Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. *Am J Med* 1994; 96: 3-9.
- [4] Cervera R, Piette JC, Font J, *et al.* Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis Rheum* 2002; 46: 1019-27.
- [5] Urbanus R, Siegerink B, Roest M, Rosendaal F, de Groot P, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. *Lancet Neurol* 2009; 8: 998-1005.
- [6] Le Thi Thuong D, Tieulie N, Costedoat N, *et al.* The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. *Ann Rheum Dis* 2005; 64: 273-8.
- [7] Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. *Obstet Gynecol* 1997; 89: 549-55.
- [8] Asherson RA. The catastrophic antiphospholipid syndrome. *J Rheumatol* 1992; 19: 508-12.
- [9] Galli M, Comfurius P, Maassen C, *et al.* Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. *Lancet* 1990; 335: 952-3.
- [10] Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. *Lancet* 1990; 336: 177-8.
- [11] McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β 2-glycoprotein I (apolipoprotein H). *Proc Natl Acad Sci USA* 1990; 87: 4120-4.
- [12] Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. *Thromb Haemost* 1991; 66: 629-32.
- [13] Harris EN, Gharavi AE, Boey ML, *et al.* Anti-cardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. *Lancet* 1983; 2: 1211-4.
- [14] Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. *Thromb Haemost* 1995; 74: 1185-90.
- [15] Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. *Arthritis Rheum* 1996; 39: 1606-7.

- [16] McNally T, Mackie IJ, Machin SJ, Isenberg DA. Increased level of $\beta 2$ glycoprotein I antigen and $\beta 2$ glycoprotein I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. *Br J Rheumatol* 1995; 34: 1031-6.
- [17] Amengual O, Atsumi T, Khamashta M, Koike T, Hughes GRV. Specificity of ELISA for antibody to $\beta 2$ -glycoprotein I in patients with antiphospholipid syndrome. *Br J Rheumatol* 1996; 35: 1239-43.
- [18] Arvieux J, Damige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulant. *Thromb Haemost* 1995; 74: 1120-5.
- [19] Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. *Thromb Haemost* 1996; 75: 721-4.
- [20] Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. *Thromb Haemost* 1997; 77: 486-91.
- [21] Atsumi T, Ieko M, Bertolaccini ML, *et al.* Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. *Arthritis Rheum* 2000; 43: 1982-93.
- [22] Wilson WA, Gharavi AE, Koike T, *et al.* International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum* 1999; 42: 1309-11.
- [23] Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. *Thromb Res* 2002; 108: 263-71.
- [24] Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. *Lupus* 2002; 11: 269-75.
- [25] Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. *J Thromb Haemost* 2004; 2: 1860-2.
- [26] Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. *Blood* 2007; 109: 422-30.
- [27] Girardi G, Berman J, Redecha P, *et al.* Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. *J Clin Invest* 2003; 112: 1644-54.
- [28] Cariou R, Tobelem G, Bellucci S, *et al.* Effect of lupus anticoagulant on antithrombotic properties of endothelial cells - Inhibition of thrombomodulin-dependent protein C activation. *Thromb Haemost* 1988; 60: 54-8.
- [29] Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new *in vitro* manifestation of lupus anticoagulant. *Blood* 1989; 71: 2426-32.
- [30] Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its factor protein S by antiphospholipid antibodies. *Br J Haematol* 1990; 76: 101-7.
- [31] Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. *Thromb Haemost* 1992; 68: 101-7.
- [32] Ieko M, Ichikawa K, Triplett DA, *et al.* Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. *Arthritis Rheum* 1999; 42: 167-74.
- [33] Nojima J, Kuratsune H, Suehisa E, *et al.* Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. *Br J Haematol* 2002 118: 577-83.
- [34] Galli M, Willems GM, Rosing J, *et al.* Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. *Br J Haematol* 2005; 129: 240-7.
- [35] Matsuda J, Gotoh M, Gohchi K, Kawasugi K, Tsukamoto M, Saitoh N. Resistance to activated protein C activity of an anti-beta 2-glycoprotein I antibody in the presence of beta 2-glycoprotein I. *Br J Haematol* 1995; 90: 204-6.
- [36] Atsumi T, Khamashta MA, Amengual O, *et al.* Binding of anticardiolipin antibodies to protein C *via* $\beta 2$ -glycoprotein I ($\beta 2$ -GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. *Clin Exp Immunol* 1998; 112: 325-33.
- [37] Izumi T, Pound ML, Su Z, Iverson GM, Ortel TL. Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids. *Thromb Haemost* 2002; 88: 620-6.
- [38] Galli M, Willems GM, Rosing J, *et al.* Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. *Br J Haematol* 2005; 129: 240-7.
- [39] Field SL, Chesterman CN, Hogg PJ. Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies. *Thromb Haemost* 2000; 84: 1132-3.
- [40] Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. *Thromb Haemost* 1996; 76: 190-4.
- [41] Ginsberg J, Demers C, Brill-Edwards P, *et al.* Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. *Am J Med* 1995; 98: 379-83.
- [42] Oosting JD, Derksen RHW, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? *Blood* 1993; 81: 2618-25.
- [43] Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I. *Thromb Haemost* 1995; 73: 798-804.
- [44] Shi T, Iverson GM, Qi JC, *et al.* Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. *Proc Natl Acad Sci U S A* 2004; 101: 3939-44.
- [45] Rahgozar S, Yang Q, Giannakopoulos B, Yan X, Miyakis S, Krilis SA. Beta2-glycoprotein I binds thrombin *via* exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. *Arthritis Rheum* 2007; 56: 605-13.
- [46] Sheng Y, Reddel SW, Herzog H, *et al.* Impaired thrombin generation in $\beta 2$ -glycoprotein I null mice. *J Biol Chem* 2001; 276: 13817-21.
- [47] Broze GJJ. Protein Z-dependent regulation of coagulation. *Thromb Haemost* 2001; 86: 8-13.
- [48] Steffano B, Forastiero R, Martinuzzo M, Kordich L. Low plasma protein Z levels in patients with antiphospholipid antibodies. *Blood Coagul Fibrinolysis* 2001; 12: 411-2.
- [49] McColl MD, Deans A, Maclean P, Tait RC, Greer IA, Walker ID. Plasma protein Z deficiency is common in women with antiphospholipid antibodies. *Br J Haematol* 2003; 20: 913-4.
- [50] Pardos-Gea J, Ordi-Ros J, Serrano S, Balada E, Nicolau I, Vilardell M. Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis. *Thromb Res* 2008; 121: 727-34.
- [51] Forastiero RR, Martinuzzo ME, Lu L, Broze GJ. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. *J Thromb Haemost* 2003; 1: 1764-70.
- [52] Francis RB, McGehee JA, Feinstein DI. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. *Thromb Haemost* 1988; 59: 412-4.
- [53] Violi F, Ferro D, Valesini G, *et al.* Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. *BMJ* 1990; 300: 1099-102.
- [54] Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. The fibrinolytic response to venous occlusion and the natural anticoagulant in patients with antiphospholipid syndrome both with and without systemic lupus erythematosus. *Br J Haematol* 1991; 77: 354-9.
- [55] Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus

- erythematosus and other connective tissue disorders. *Thromb Haemost* 1992; 68: 516-20.
- [56] Ieko M, Ichikawa K, Atsumi T, *et al.* Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. *Semin Thromb Hemost* 2000; 26: 85-90.
- [57] Takeuchi R, Atsumi T, Ieko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. *Br J Haematol* 2002; 119: 781-8.
- [58] Carmona F, Lazaro I, Reverter JC, *et al.* Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. *Am J Obstet Gynecol* 2006; 194: 457-65.
- [59] Cugno M, Cabibbe M, Galli M, *et al.* Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. *Blood* 2004; 103: 2121-6.
- [60] Yang C, Hwang KK, Yan W, *et al.* Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. *J Immunol* 2004; 172: 5765-73.
- [61] Kolev K, Gombas J, Varadi B, *et al.* Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. *Thromb Haemost* 2002; 87: 502-8.
- [62] Tziomalos K, Athyros V, Wierzbicki A, Mikhailidis D. Lipoprotein a: where are we now? *Curr Opin Cardiol* 2009; 24: 351-7.
- [63] Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. *J Biol Chem* 1991; 266: 2459-65.
- [64] Atsumi T, Khamashta MA, Andujar C, *et al.* Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. *J Rheumatol* 1998; 25: 69-73.
- [65] Yamazaki M, Asakura H, Jokaji H, *et al.* Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. *Thromb Haemost* 1994; 71: 424-7.
- [66] Simantov R, LaSala JM, Lo SK, *et al.* Activation of cultured vascular endothelial cells by antiphospholipid antibodies. *J Clin Invest* 1995; 96: 2211-9.
- [67] Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. *Circ Res* 2001; 88: 245-50.
- [68] Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. *J Immunol* 1994; 153: 1328-32.
- [69] Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. *Thromb Haemost* 1998; 79: 276-81.
- [70] Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. *Am J Obstet Gynecol* 1993; 168: 206-10.
- [71] Reverter JC, Tassies D, Font J, *et al.* Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. *Arthritis Rheum* 1998; 41: 1420-7.
- [72] Atsumi T, Khamashta MA, Haworth RS, *et al.* Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. *Arthritis Rheum* 1998; 41: 800-7.
- [73] Del Papa N, Sheng YH, Raschi E, *et al.* Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. *J Immunol* 1998; 160: 5572-8.
- [74] Meroni PL, Raschi E, Camera M, *et al.* Endothelial activation by aPL: a potential pathogenic mechanism for the clinical manifestations of the syndrome. *J Autoimmun* 2000; 15: 237-40.
- [75] Vega-Ostertag M, Liu X, Kwan-Ki H, Chen P, Pierangeli S. A human monoclonal antiprothrombin antibody is thrombogenic *in vivo* and upregulates expression of tissue factor and E-selectin on endothelial cells. *Br J Haematol* 2006; 135: 214-9.
- [76] Dignat-George F, Camoin-Jau L, Sabatier F, *et al.* Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. *Thromb Haemost* 2004; 91: 667-73.
- [77] Nakamura N, Ban T, Yamaji K, Yoneda Y, Wada Y. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. *J Clin Invest* 1998; 101: 1951-9.
- [78] Nojima J, Suehisa E, Kuratsune H, *et al.* Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus—possible association with thrombotic and thrombocytopenic complications. *Thromb Haemost* 1999; 81: 436-4.
- [79] Emmi L, Bergamini C, Spinelli A, *et al.* Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. *Ann N Y Acad Sci* 1997; 823: 188-200.
- [80] Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. *Thromb Haemost* 1998; 79: 42-5.
- [81] Nimpf J, Bevers EM, Bomans PH, *et al.* Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. *Biochim Biophys Acta* 1986; 884: 142-9.
- [82] Shi W, Chong BH, Chesterman CN. β 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. *Blood* 1993; 81: 1255-62.
- [83] Vazquez-Mellado J, Llorente L, Richaud-Patin Y, Alarcon-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. *J Autoimmun* 1994; 7: 335-48.
- [84] Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. *J Biol Chem* 2000; 275: 15541-8.
- [85] Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. *Blood* 2005; 105: 1964-9.
- [86] Raschi E, Testoni C, Bosisio D, *et al.* Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. *Blood* 2003; 101: 3495-500.
- [87] Satta N, Dunoyer-Geindre S, Reber G, *et al.* The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. *Blood* 2007; 109: 1507-14.
- [88] Meroni PL, Raschi E, Testoni C, Parisio A, Borghi MO. Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. *Autoimmun Rev* 2004; 3: 510-5.
- [89] Shi T, Giannakopoulos B, Yan X, *et al.* Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner *via* glycoprotein Ib-IX-V. *Arthritis Rheum* 2006; 54: 2558-67.
- [90] Pennings MT, Derksen RH, van Lummel M, *et al.* Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein I α and apolipoprotein E receptor 2. *J Thromb Haemost* 2007; 5: 369-77.
- [91] de Groot PG, Derksen RH, Urbanus RT. The role of LRP8 (ApoER2) in the pathophysiology of the antiphospholipid syndrome. *Lupus* 2010; 389-93.
- [92] Vlachoyiannopoulos PG, Routsias JG. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. *J Autoimmunity* 2010; 35: 248-55.
- [93] Meroni PL, Raschi E, Testoni C, *et al.* Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. *Arthritis Rheum* 2001; 44: 2870-8.
- [94] Dunoyer-Geindre S, De Moerloose P, Galve-De Rochemonteix B, Reber G, Kruihof E. NF κ B is an essential intermediate in the activation of endothelial cells by anti-beta(2) glycoprotein I antibodies. *Thromb Haemost* 2002; 88: 851-7.
- [95] Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. *J Thromb Haemost* 2003; 1: 843-8.

- [96] Bohgaki M, Atsumi T, Yamashita Y, *et al*. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. *Int Immunol* 2004; 16: 1633-41.
- [97] Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. *Arthritis Rheum* 2004; 50: 2911-9.
- [98] Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. *Arthritis Rheum* 2005; 52: 1545-54.
- [99] Nakajima K, Tohyama Y, Kohsaka S, Kurihara T. Protein kinase C alpha requirement in the activation of p38 mitogen-activated protein kinase, which is linked to the induction of tumor necrosis factor alpha in lipopolysaccharide-stimulated microglia. *Neurochem Int* 2004; 44: 205-14.
- [100] Sorice M, Longo A, Capozzi A, *et al*. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. *Arthritis Rheum* 2007; 56: 2687-97.
- [101] Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. *Nat Med* 2004; 10: 1222-6.
- [102] Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. *Nat Clin Pract Rheumatol* 2007; 3: 140-7.
- [103] Sugiura-Ogasawara M, Nozawa K, Nakanishi T, Hattori Y, Ozaki Y. Complement as a predictor of further miscarriage in couples with recurrent miscarriages. *Hum Reprod* 2006; 21: 2711-4.
- [104] Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. *Clin Exp Rheumatol* 1992; 10: 455-60.
- [105] Oku K, Atsumi T, Bohgaki M, *et al*. Complement activation in patients with primary antiphospholipid syndrome. *Ann Rheum Dis* 2009; 68: 1030-5.
- [106] Sammaritano LR, Ng S, Sobel R, *et al*. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. *Arthritis Rheum* 1997; 40: 1998-2006.
- [107] Amengual O, Atsumi T, Khamashta MA, Bertolaccini ML, Hughes GR. IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome. *Arthritis Rheum* 1998; 41: 1513-5.
- [108] Hannaford P. Epidemiology of the contraceptive pill and venous thromboembolism. *Thromb Res* 2011; 127: 30-4.
- [109] Erkan D, Patel S, Nuzzo M, *et al*. Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. *Rheumatology* 2008; 47: 23-7.
- [110] Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A Systematic Review of Secondary Thromboprophylaxis in Patients With Antiphospholipid Antibodies. *Arthritis Rheum* 2007; 57: 1487-95.
- [111] Ruiz-Irastorza G, Khamashta MA. The treatment of antiphospholipid syndrome: a harmonic contrast. *Best Pract Res Clin Rheumatol* 2007; 21: 1079-92.
- [112] Carp HJ, Asherson RA, Shoenfeld Y. Intravenous immunoglobulin in pregnancies complicated by the antiphospholipid syndrome: what is its role? *J Clin Rheumatol* 2001; 7: 291-4.
- [113] Chang P, Millar D, Tsang P, Lim K, Houlihan E, Stephenson M. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. *Am J Perinatol* 2006; 23: 125-9.
- [114] Hereng T, Lambert M, Hachulla E, *et al*. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. *Lupus* 2008; 17: 11-5.
- [115] Erkan D, Harrison M, Levy R, *et al*. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. *Arthritis Rheum* 2007; 56: 2382-91.
- [116] Diener HC. Antiplatelet agents and randomized trials. *Rev Neurol Dis* 2007; 4: 177-83.
- [117] Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by diltiazem. *Blood* 2004; 104: 2353-8.
- [118] Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. *Immunobiology* 2005; 210: 727-33.
- [119] Ruckert A, Glimm H, Lubbert M, Grulich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. *Lupus* 2008; 17: 757-60.
- [120] Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. *Lupus* 2008; 17: 50-5.
- [121] Kumar D, Roubey RA. Use of rituximab in the antiphospholipid syndrome. *Curr Rheumatol Rep* 2010; 12: 40-4.
- [122] Ozaki M, Ogata M, Yokoyama T, Kawasaki T, Shigematsu A, Sata T. Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. *Can J Anaesth* 2005; 52: 143-7.
- [123] Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. *Scand J Rheumatol* 1996; 25: 191-3.
- [124] Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. *Thromb Haemost* 2002; 87: 518-22.
- [125] Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. *Circulation* 1997; 96: 4380-4.
- [126] Erkan D, Derksen WJ, Kaplan V, *et al*. Real world experience with antiphospholipid antibody tests: how stable are results over time? *Ann Rheum Dis* 2005; 64: 1321-5.
- [127] Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. *Thromb Res* 2004; 114: 467-76.
- [128] Ferrara DE, Swerlick R, Casper K, *et al*. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. *J Thromb Haemost* 2004; 2: 1558-63.
- [129] Pierangeli SS, Ferrara DE. More on: fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. *J Thromb Haemost* 2005; 3: 1112-3.
- [130] Ferrara DE, Liu X, Espinola RG, *et al*. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an *in vivo* animal model. *Arthritis Rheum* 2003; 48: 3272-9.
- [131] Furberg CD, Adams HP Jr, Applegate WB, *et al*. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. *Circulation* 1994; 90: 1679-87.
- [132] Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAF2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. *J Clin Invest* 2008; 118: 3453-61.
- [133] Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. *Circ Res* 2000; 86: 139-43.
- [134] Soejima H, Ogawa H, Yasue H, *et al*. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. *J Am Coll Cardiol* 1999; 34: 983-8.
- [135] Andersson P, Cederholm T, Johansson AS, Palmblad J. Captopril-impaired production of tumor necrosis factor-alpha-induced interleukin-1beta in human monocytes is associated with altered intracellular distribution of nuclear factor-kappaB. *J Lab Clin Med* 2002; 140: 103-9.
- [136] Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. *Am J Pathol* 1998; 153: 1825-37.
- [137] Schmeisser A, Soehnlein O, Illmer T, *et al*. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. *Biochem Biophys Res Commun* 2004; 325: 532-40.

- [138] de Groot PG, Horbach DA, Derksen RH. Protein C and other co-factors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. *Lupus* 1996; 5: 488-93.
- [139] Levi M. Activated protein C in sepsis: a critical review. *Curr Opin Hematol* 2008; 15: 481-6.
- [140] Ikezoe T, Ikenoue N, Uchikawa N, Kojima S, Fukaya T, Yokoyama A. Use of recombinant human soluble thrombomodulin in the management of HELLP syndrome complicated by DIC. *Thromb Res* 2010; 126: 238-40.
- [141] Curzio KM, Cheng-Lai A, Kheyfets V, Sinnet M, Billett HH. A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience. *J Thromb Thrombolysis* 2008.
- [142] Stone GW, Witzenbichler B, Guagliumi G, *et al.* Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med* 2008; 358: 2218-30.
- [143] Spyropoulos AC. Brave new world: The current and future use of novel anticoagulants. *Thromb Res* 2008; 123 Suppl: 29-35.
- [144] Bauer KA. New anticoagulants. *Curr Opin Hematol* 2008; 15: 509-15.
- [145] Turpie AG, Lassen MR, Davidson BL, *et al.* Rivaroxaban vs. enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet* 2009; 373: 1673-80.
- [146] Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. *Thromb Haemost* 2009 101: 77-85.
- [147] Moons AH, Peters RJ, Bijsterveld NR, *et al.* Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. *J Am Coll Cardiol* 2003 41: 2147-53.
- [148] Blank M, Krause I, Wildbaum G, Karin N, Shoenfeld Y. TNF α DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. *Lupus* 2003; 12: 546-9.
- [149] Berman J, Girardi G, Salmon JE. TNF- α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. *J Immunol* 2005; 174: 485-90.
- [150] Jonsdottir T, Forslid J, van Vollenhoven A, *et al.* Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. *Ann Rheum Dis* 2004; 63: 1075-8.
- [151] Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. *Arthritis Rheum* 2007; 56: 274-9.
- [152] Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. *Arthritis Res Ther* 2004; 6: R535-43.
- [153] Montiel-Manzano G, Romay-Penabad Z, Papalardo de Martinez E, *et al.* *In vivo* effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. *Ann N Y Acad Sci* 2007; 1108: 540-53.
- [154] Lopez-Pedreira C, Buendia P, Cuadrado MJ, *et al.* Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins *via* the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. *Arthritis Rheum* 2006; 54: 301-11.
- [155] Mann K. Biochemistry and physiology of blood coagulation. *Thromb Haemost* 1999; 82: 165-74.
- [156] Cuadrado MJ, Lopez-Pedreira C, Khamashta MA, *et al.* Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. *Arthritis Rheum* 1997; 40: 834-41.
- [157] Forastiero RR, Martinuzzo ME, de Larranaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. *Lupus* 2005; 14: 129-36.
- [158] Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. *J Rheumatol* 2003; 29: 2006-11.
- [159] Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. *Thromb Haemost* 1995; 73: 529-34.
- [160] Jimenez S, Tassies D, Espinosa G, *et al.* Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. *Ann Rheum Dis* 2008; 67: 835-40.
- [161] Mandava P, Thiagarajan P, Kent TA. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. *Drugs* 2008; 68: 1019-28.
- [162] Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen *via* interaction with phospholipids and the apolipoprotein E receptor 2'. *J Biol Chem* 2003; 278: 33831-8.
- [163] Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. β_2 Glycoprotein I (β_2 GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. *Blood* 2010; 115: 713-23.
- [164] Robbins DL, Leung S, Miller-Blair DJ, Ziboh V. Effect of anticardiolipin/ β_2 -glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. *J Rheumatol* 1998; 25: 51-6.
- [165] Wang L, Su CY, Chou KY, Wang CT. Enhancement of human platelet activation by the combination of low concentrations of collagen and rabbit anticardiolipin antibodies. *Br J Haematol* 2002; 118: 1152-62.
- [166] Opara R, Robbins DL, Ziboh VA. Cyclic-AMP agonists inhibit antiphospholipid/ β_2 -glycoprotein I induced synthesis of human platelet thromboxane A2 *in vitro*. *J Rheumatol* 2003; 30: 55-9.
- [167] Shoenfeld Y, Blank M. Effect of long-acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome. *Lupus* 1994; 3: 397-400.
- [168] Holers VM, Girardi G, Mo L, *et al.* Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. *J Exp Med* 2002; 195: 211-20.
- [169] Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. *Arthritis Rheum* 2005; 52: 2120-4.
- [170] Blank M, Krause I, Lanir N, *et al.* Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell. *Arthritis Rheum* 1995; 38: 115-22.
- [171] Blank M, Tomer Y, Slavin S, Shoenfeld Y. Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation. *Scand J Immunol* 1995; 42: 226-34.
- [172] Bohgaki T, Atsumi T, Koike T. Multiple autoimmune diseases after autologous stem-cell transplantation. *N Engl J Med* 2007; 357: 2734-6.
- [173] Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to β_2 (2)-glycoprotein I in patients with antiphospholipid syndrome. *Blood* 2007; 110: 4312-8.
- [174] Atsumi T. New therapeutic targets for antiphospholipid syndrome. *Blood* 2007; 110: 4141.
- [175] Blank M, George J, Barak V, Tincani A, Koike T, Shoenfeld Y. Oral tolerance to low dose β_2 -glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. *J Immunol* 1998; 161: 5303-12.
- [176] Merrill JT. LJP 1082: a toleragen for Hughes syndrome. *Lupus* 2004; 13: 335-8.
- [177] Cockerill KA, Iverson GM, Jones DS, Linnik MD. Therapeutic potential of toleragens in the management of antiphospholipid syndrome. *BioDrugs* 2004; 18: 297-305.